Biogen (BIIB) Gains 5% on Strong Q4 Results, Promising Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Biogen (BIIB) Pushes Higher Following EPS
January 27, 2016 11:55 AM ESTBiogen (NASDAQ: BIIB) is pushing to the highs of the session following strong earnings and a solid outlook. Shares are now up 7.9%
... MoreBiogen (BIIB) Tops Q4 EPS by 42c; Guides In-Line
January 27, 2016 7:16 AM ESTBiogen (NASDAQ: BIIB) reported Q4 EPS of $4.50, $0.42 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.84 billion versus the consensus estimate of $2.71 billion.
GUIDANCE:
Biogen sees FY2016 EPS of $18.30-$18.60, versus the consensus of $18.45. Biogen sees FY2016 revenue of $11.1-11.3 billion, versus the consensus of $11.29 billion.
We saw solid performance in our industry leading multiple sclerosis portfolio and strong... More
